Impact of antiretroviral therapy during primary HIV infection on T‐cell immunity after treatment interruption
European Journal of Immunology · 2024
DOI: 10.1002/eji.202451200 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Immunology, 2024. Verfasst von Timothy Tipoe und 12 weiteren Autor:innen. Beteiligte Einrichtung: Peter Medawar Building for Pathogen Research, Nuffield Dept of Medicine, University of Oxford, Oxford, UK. Hauptthemen laut MEDLINE: HIV Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This study aims to understand the impact of early antiretroviral therapy (ART) on HIV‐specific T‐cell responses measured after treatment interruption, which may inform strategies to deliver ART‐free immune‐mediated viral suppression. HIV‐specific T‐cell immunity was analysed using gamma interferon enzyme‐linked immunospot assays in two studies. SPARTAC included individuals with primary HIV infection randomised to 48 weeks of ART ( n = 24) or no immediate therapy ( n = 37). The PITCH ( n = 7) cohort started antiretroviral therapy in primary infection for at least one year, followed by TI. In SPARTAC, participants treated in PHI for 48 weeks followed by TI for 12 weeks, and those who remained untreated for 60 weeks made similar HIV Gag‐directed responses (both magnitude and breadth) at week 60. However, the treated group made a greater proportion of novel HIV Gag‐directed responses by Week 60, suggestive of a greater reserve to produce new potentially protective responses. In the more intensively followed PITCH study, 6/7 participants showed dominant Gag and/or Pol‐specific responses post‐TI compared with pre‐TI. Although early ART in PHI was not associated with major differences in HIV‐specific immunity following TI compared with untreated participants, the potential to make more new Gag‐directed responses warrants further investigation as this may inform strategies to achieve ART‐free control.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Peter Medawar Building for Pathogen Research, Nuffield Dept of Medicine, University of Oxford, Oxford, UK.
- Department of HIV Medicine, St Mary's Hospital, Imperial College Healthcare NHS Trust, London, UK.
- Department of Infectious Disease, Imperial College London, London, UK.
- Barts Health NHS Trust, London, UK.
- Guy's and St Thomas' NHS Foundation Trust, London, UK.
- NIHR Clinical Research Facility, Guys and St Thomas' NHS Trust, London, UK.
Zitieren
APA
Tipoe, T., Ogbe, A., Lee, M., Brown, H., Robinson, N., Hall, R., Petersen, C., Lewis, H., Thornhill, J., Ryan, F., Fox, J., Fidler, S., & Frater, J. (2024). Impact of antiretroviral therapy during primary HIV infection on T‐cell immunity after treatment interruption. European Journal of Immunology. https://doi.org/10.1002/eji.202451200
Vancouver
Tipoe T, Ogbe A, Lee M, Brown H, Robinson N, Hall R, et al. Impact of antiretroviral therapy during primary HIV infection on T‐cell immunity after treatment interruption. European Journal of Immunology. 2024. doi:10.1002/eji.202451200
BibTeX
@article{Tipoe2024,
author = {Tipoe, Timothy and Ogbe, Ane and Lee, Ming and Brown, Helen and Robinson, Nicola and Hall, Rebecca and Petersen, Claire and Lewis, Heather and Thornhill, John and Ryan, Fiona and Fox, Julie and Fidler, Sarah and Frater, John},
title = {Impact of antiretroviral therapy during primary HIV infection on T‐cell immunity after treatment interruption},
journal = {European Journal of Immunology},
year = {2024},
doi = {10.1002/eji.202451200}
}
EUVIMED